Results 71 to 80 of about 11,211 (144)

Once-Daily Dolutegravir-Based Antiretroviral Therapy Among Adults With Advanced HIV Disease Receiving 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis-Preventive Therapy and Fluconazole for Treatment of Cryptococcal Meningitis: Results of a Pharmacokinetic Study. [PDF]

Open Forum Infect Dis
Ellis J, Hale G, Buzibye A, Omali D, Naluyima S, Ntenkaire N, Nsangi LJ, Ndyetukira JF, Sadiq A, Ahimbisibwe C, Nabbaale S, Tukundane A, Bakka W, Gakuru J, Kawuma AN, Cresswell FV, Moore DAJ, Meya DB, Boulware DR, Waitt C, Jarvis JN, Nicol MR.   +21 more
europepmc   +1 more source

Virological and metabolic outcomes after switching to dolutegravir or rilpivirine in virologically suppressed adults with HIV in Thailand: an open-label, randomised, controlled, non-inferiority trial. [PDF]

Lancet Reg Health Southeast Asia
Kajeekul R, Ruenroengbun N, Wiwatrojanagul S, Kirdtongkum K, Chantaranothai W, Bin Khalid KE, Sirijatuphat R, Ngamprasertchai T.   +7 more
europepmc   +1 more source

Atazanavir/Ritonavir-Associated Erythema Multiforme in an HIV-1-Positive Patient. [PDF]

Cureus
Singh RK.
europepmc   +1 more source

Incidence of neonatal sepsis among HIV exposed neonates of mothers on integrase strand transfer inhibitors in sub-Saharan Africa: a systematic review and meta-analysis. [PDF]

BMC Infect Dis
Pebolo PF, Bongomin F, Morgan B, Pitua I, Nantale R, Omona V, Ngonzi J, Hamer DH.   +7 more
europepmc   +1 more source

High Levels of Elevated Blood Pressure Among Pregnant and Postpartum Women With HIV, Regardless of Dolutegravir Initiation. [PDF]

Clin Infect Dis
Bengtson AM.
europepmc   +1 more source

Pharmaceutical Sovereignty as HIV Justice: Colombia's Dolutegravir License and the Future of ART Access in Latin America. [PDF]

J Int AIDS Soc
Cifuentes LM, Brisson JB, Zea A, David PM.   +3 more
europepmc   +1 more source

Multiclass HIV drug resistance: Case series of treatment-experienced PLHIV with resistance to all antiretroviral classes in Northern Uganda. [PDF]

IDCases
Kayinda F, Bakunzi LB, Okello E, Jurua C, Nasuuna EM.   +4 more
europepmc   +1 more source

Simulation-Based Predictions to Support the Development of a Pediatric Fixed-Dose Combination of Dolutegravir/Emtricitabine/Tenofovir Alafenamide Fumarate. [PDF]

Clin Pharmacokinet
Waalewijn H, Bevers LAH, Lewis LL, Louey MD, Kawakatsu S, Zheng Y, Giaquinto C, Nardone A, Burger DM, Ter Heine R, Colbers A, Svensson EM.   +11 more
europepmc   +1 more source

Dolutegravir population pharmacokinetics in racially, sex- and age-diverse and antiretroviral therapy-experienced adults with HIV in the United States. [PDF]

HIV Med
Khoei A, Edmonds A, Chang Y, Ramirez C, Vogan M, Poliseno A, Wolinsky S, Ho K, Brown TT, Margolick JB, Batson J, Hoffmann J, Marzinke MA, Kempf MC, Alcaide ML, Effoe J, Lahiri CD, Ofotokun I, Sheth AN, Gange S, French AL, Tamraz B, Aouizerat BE, Tien PC, Kassaye SG, DeHovitz J, Anastos K, Chew KW, Floris-Moore M, Dumond JB.   +29 more
europepmc   +1 more source

Pharmacokinetics of abacavir and lamivudine in infants living with HIV with and without rifampicin co-treatment. [PDF]

J Antimicrob Chemother
Beca LSDAB, Mumbiro V, Bwakura M, Mujuru HA, Mudzingwa S, Tagarro A, Domínguez-Rodríguez S, Musiime V, Nalwanga D, Buck WC, Sacarlal J, Chabala C, Chansa BN, Rojo P, Burger DM, Moraleda C, Jacobs TG, EMPIRICAL Clinical Trial Group.   +17 more
europepmc   +1 more source